Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review

Bassendine, Margaret F. and Bridge, Simon (2020) Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. European Journal of Rheumatology, 7 (1). pp. 37-40. ISSN 2147-9720

Preview

Text 37-40.pdf - Published Version Available under License Creative Commons Attribution Non-commercial 4.0. Download (95kB) | Preview

Abstract

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatological condition affecting individuals aged >50 years. There have been rare reports of PMR and other vasculitides developing within 3 months of influenza vaccination. Influenza is a major public health issue associated with seasonal increased mortality and intensified health care service use. Annual vaccination is the most effective intervention to prevent influenza, especially in elderly individuals. We report a severe “flare” of PMR in a 70-year-old patient after receiving the adjuvanted trivalent influenza vaccine, as recommended by the Joint Committee on Vaccination and Immunisations for this age group in the UK National Health Service in 2018-2019. The adverse event (AE) could be interpreted as the newly described autoimmune/inflammatory syndrome induced by adjuvants (ASIA syndrome) as both PMR and ASIA display hyperactive immune responses. Caution is warranted in the use of vaccine adjuvants in patients with PMR with pre-existing imbalance of B and T cell homeostasis. Rare AEs are important to individuals, and personalized medicine means we should move away from “one size fits all” for vaccines, as well as for therapeutics.

Actions (login required)

View Item

Downloads